NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CTSO

Cytosorbents Corp

Jul 03 • 04:00PM ET

1.09

Dollar change +0.09
Percentage change 9.00	%

Healthcare • Medical Devices • USA • NASD

Peers: MDT ABT BSX BAX RMD EW DXCM PEN TFX GMED

| Held by: VTI VXF IWC MSSM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	17.05%	Shs Outstand	62.53M	Perf Week	-7.63%
Market Cap	68.25M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	0.00%	Shs Float	51.94M	Perf Month	9.00%
Enterprise Value	83.89M	PEG	-	EPS next Q	-0.04	Inst Own	32.88%	Short Float	2.76%	Perf Quarter	9.00%
Income	-15.84M	P/S	1.98	EPS this Y	42.83%	Inst Trans	3.50%	Short Ratio	12.05	Perf Half Y	21.11%
Sales	34.54M	P/B	4.69	EPS next Y	44.30%	ROA	-32.37%	Short Interest	1.43M	Perf YTD	19.78%
Book/sh	0.23	P/C	5.89	EPS next 5Y	-	ROE	-94.65%	52W High	1.61 -32.30%	Perf Year	55.71%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	12.41% 8.62%	ROIC	-38.59%	52W Low	0.71 53.50%	Perf 3Y	-51.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.23% 7.37%	Gross Margin	68.53%	Volatility	10.29% 9.75%	Perf 5Y	-88.56%
Dividend TTM	-	EV/Sales	2.43	EPS Y/Y TTM	50.76%	Oper. Margin	-52.33%	ATR (14)	0.12	Perf 10Y	-84.99%
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	-5.86%	Profit Margin	-45.86%	RSI (14)	49.00	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.61	EPS Q/Q	79.27%	SMA20	-5.18%	Beta	1.23	Target Price	5.50
Payout	-	Debt/Eq	1.87	Sales Q/Q	-10.82%	SMA50	7.65%	Rel Volume	1.70	Prev Close	1.00
Employees	149	LT Debt/Eq	1.82	Earnings	May 14 AMC	SMA200	5.20%	Avg Volume	118.94K	Price	1.09
IPO	Aug 08, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.69% -5.25%	Trades		Volume	201,856	Change	9.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-07-23	Initiated	B. Riley Securities	Buy	$4
Oct-14-21	Resumed	B. Riley Securities	Buy	$10
Sep-17-20	Initiated	Jefferies	Buy	$15
Sep-01-20	Initiated	SVB Leerink	Outperform	$15
Aug-08-17	Reiterated	Maxim Group	Buy	$10 → $12
Oct-26-16	Initiated	Aegis Capital	Buy
May-24-16	Initiated	Maxim Group	Buy	$8
Oct-29-15	Upgrade	WBB Securities	Speculative Buy → Buy	$13 → $13
May-12-15	Reiterated	MLV & Co	Buy	$28 → $21
Apr-01-15	Reiterated	MLV & Co	Buy	$28 → $30
Mar-05-15	Initiated	MLV & Co	Buy	$30
Feb-25-15	Initiated	WBB Securities	Speculative Buy	$13
Jan-27-15	Reiterated	H.C. Wainwright	Buy	$1 → $12

Show Previous Ratings

Jul-02-25 07:00AM	CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR (PR Newswire) -22.48%
Jun-24-25 07:00AM	CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR (PR Newswire)
May-29-25 07:00AM	CytoSorbents to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
May-22-25 09:27AM	CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025 (PR Newswire)
May-15-25 08:58AM	Q1 2025 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Loading…
03:16AM	CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
May-14-25 04:50PM	CytoSorbents: Q1 Earnings Snapshot (Associated Press Finance) -7.11%
04:01PM	CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
May-13-25 09:47AM	CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-01-25 04:15PM	CytoSorbents Provides Regulatory Update for DrugSorb-ATR (PR Newswire) -6.93%
Apr-29-25 07:00AM	CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Apr-21-25 07:00AM	CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program (PR Newswire) +5.83%
Apr-17-25 07:00AM	CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller (PR Newswire)
Apr-14-25 07:00AM	CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America (PR Newswire)
Apr-04-25 07:00AM	CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants (PR Newswire)
06:44AM	Loading…
Apr-01-25 06:44AM	Q4 2024 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
03:04AM	CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-31-25 07:51PM	Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:59PM	CytoSorbents: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (PR Newswire)
Mar-24-25 09:05AM	CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Mar-21-25 07:00AM	CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit (PR Newswire) -9.77%
Mar-05-25 07:32AM	CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +14.00%
Mar-04-25 07:00AM	CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller (GlobeNewswire)
Feb-26-25 07:00AM	CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-25-25 07:00AM	CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants (GlobeNewswire)
Jan-14-25 09:35AM	Cytosorbents Boosts Liquidity with Successful Rights Offering (TipRanks)
Jan-13-25 07:00AM	CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering (GlobeNewswire) +11.98%
Jan-06-25 07:00AM	CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai (GlobeNewswire) +11.04%
Jan-04-25 08:15AM	CytoSorbents reported strong Q4 results, says D. Boral Capital (TipRanks)
07:00AM	Loading…
Jan-03-25 07:00AM	CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue (GlobeNewswire)
Dec-23-24 07:00AM	CytoSorbents Rights Offering Begins (GlobeNewswire) -8.37%
Dec-12-24 07:00AM	CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week (GlobeNewswire)
Dec-09-24 07:00AM	CytoSorbents Announces Rights Offering (GlobeNewswire)
Nov-26-24 07:00AM	CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-11-24 07:30AM	CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India (GlobeNewswire) +25.68%
Nov-08-24 04:03PM	CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ... (GuruFocus.com) -18.05%
Nov-07-24 05:58PM	CytoSorbents: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CytoSorbents Reports Third Quarter 2024 Financial and Operational Results (GlobeNewswire)
Nov-06-24 07:54AM	CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +6.61%
Nov-04-24 07:00AM	CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification (GlobeNewswire) -12.95%
Oct-22-24 07:00AM	FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review (GlobeNewswire)
Oct-17-24 07:00AM	CytoSorbents to Report Third Quarter 2024 Operating and Financial Results (GlobeNewswire)
Oct-09-24 06:19PM	CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) -7.08%
Oct-01-24 07:00AM	CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update (GlobeNewswire) -10.00%
Aug-27-24 07:00AM	CytoSorbents to Present at the H.C. Wainwright 26?? Annual Global Investment Conference (GlobeNewswire)
Aug-16-24 04:05PM	CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-24 05:45PM	CytoSorbents: Q2 Earnings Snapshot (Associated Press Finance) +7.99%
04:19PM	CytoSorbents Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) +7.92%
Aug-01-24 07:00AM	CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-30-24 02:00AM	CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website (GlobeNewswire)
Jul-29-24 08:00AM	CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website (GlobeNewswire) +17.48%
Jul-17-24 07:00AM	CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress (GlobeNewswire)
Jul-02-24 07:00AM	CytoSorbents Secures $20 Million Credit Facility (GlobeNewswire) +17.40%
Jun-24-24 07:00AM	CytoSorbents Announces Regulatory Approval of CytoSorb in Taiwan (GlobeNewswire)
Jun-13-24 07:00AM	CytoSorbents Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union (GlobeNewswire)
Jun-05-24 07:00AM	CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting (GlobeNewswire) +5.04%
Jun-04-24 07:00AM	CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract (GlobeNewswire)
May-10-24 12:10PM	Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript (Insider Monkey) +12.30%
May-09-24 04:24PM	CytoSorbents: Q1 Earnings Snapshot (Associated Press Finance) -7.10%
04:17PM	CytoSorbents Reports First Quarter 2024 Results (GlobeNewswire)
May-02-24 07:00AM	CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe (GlobeNewswire)
Apr-26-24 07:00AM	CytoSorbents to Report First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Apr-17-24 07:00AM	STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting (GlobeNewswire)
Mar-15-24 10:14AM	Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.27%
06:28AM	Q4 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 09:53PM	CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:39PM	CytoSorbents Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-06-24 07:00AM	CytoSorbents to Report Fiscal 2023 Operating and Financial Results (GlobeNewswire)
Feb-08-24 07:00AM	CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-17-24 07:15AM	Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients (GlobeNewswire)
Dec-28-23 07:00AM	CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation (GlobeNewswire) -33.44%
Dec-16-23 07:01AM	Insider Buying: CEO Phillip Chan Acquires 75,188 Shares of CytoSorbents Corp (CTSO) (GuruFocus.com)
Dec-13-23 09:15AM	CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering (GlobeNewswire) +21.53%
Nov-10-23 09:42AM	Q3 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
08:52AM	Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 05:47PM	CytoSorbents: Q3 Earnings Snapshot (Associated Press Finance) -11.27%
04:15PM	CytoSorbents Reports Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-27-23 07:00AM	CytoSorbents to Report Third Quarter 2023 Operating and Financial Results (GlobeNewswire) -7.83%
Oct-05-23 07:00AM	CytoSorbents to Present at the 8th Annual Dawson James Conference (GlobeNewswire)
Sep-27-23 07:00AM	CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-19-23 07:00AM	CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer (GlobeNewswire)
Sep-11-23 11:32AM	CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation (GlobeNewswire)
Sep-01-23 04:43PM	CytoSorbents Announces Resignation of Chief Financial Officer Alexander DAmico (GlobeNewswire)
Aug-31-23 07:00AM	CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil (GlobeNewswire)
Aug-14-23 07:00AM	CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial (PR Newswire)
Aug-03-23 09:10AM	CTSO: CytoSorbents reports 2nd quarter 2023 financial and results which showed strong product revenue growth and an improved cost structure. (Zacks Small Cap Research) -5.07%
Aug-02-23 09:02AM	Q2 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents) -7.46%
Aug-01-23 04:23PM	CytoSorbents: Q2 Earnings Snapshot (AP Finance)
04:15PM	CytoSorbents Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Jul-31-23 07:31AM	Several Insiders Invested In Cytosorbents Flagging Positive News (Simply Wall St.)
Jul-26-23 07:00AM	CytoSorbents to Report Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-19-23 07:00AM	CytoSorbents Appoints Alexander DAmico as Chief Financial Officer (GlobeNewswire)
Jul-11-23 07:00AM	CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease (GlobeNewswire) +11.49%
Jul-09-23 09:00AM	Cytosorbents Corporation's (NASDAQ:CTSO) largest shareholders are retail investors with 52% ownership, institutions own 33% (Simply Wall St.)
Jul-07-23 07:07AM	CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial (GlobeNewswire)
Jun-15-23 07:00AM	CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review (GlobeNewswire)

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARIANI PETER J	Chief Financial Officer	Dec 13 '24	Buy	0.96	20,000	19,294	401,363	Dec 16 07:00 AM
MARIANI PETER J	Chief Financial Officer	Dec 12 '24	Buy	0.89	20,000	17,872	381,363	Dec 13 08:00 AM
MARIANI PETER J	Chief Financial Officer	Dec 11 '24	Buy	0.89	11,363	10,103	361,363	Dec 13 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTSO

Cytosorbents Corp

Upgrade your FINVIZ experience